

Koutaro Yokote

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8633184/publications.pdf>

Version: 2024-02-01

111
papers

3,262
citations

186265

28
h-index

168389

53
g-index

119
all docs

119
docs citations

119
times ranked

4507
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabolic surgery in treatment of obese Japanese patients with type 2 diabetes: a joint consensus statement from the Japanese Society for Treatment of Obesity, the Japan Diabetes Society, and the Japan Society for the Study of Obesity. <i>Diabetology International</i> , 2022, 13, 1-30.	1.4	15
2	Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2. <i>Vaccine</i> , 2022, 40, 2129-2133.	3.8	2
3	Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <sc>STEP</sc> 1 trial extension. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1553-1564.	4.4	151
4	Clinical Usefulness of the Growth Hormoneâ€“Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder. <i>Journal of the Endocrine Society</i> , 2022, 6, .	0.2	2
5	LCAT-trial-24 weeks: Protocol for a clinical study to evaluate the safety of regenerative medicine and gene therapy by the autologous transplantation of human lecithin:cholesterol acyltransferase gene-transduced human pre-adipocytes. <i>Contemporary Clinical Trials Communications</i> , 2022, 28, 100946.	1.1	1
6	Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIMEâ€“V study). <i>Journal of Diabetes Investigation</i> , 2021, 12, 200-206.	2.4	14
7	Determinants and impact of physical impairment in patient-reported outcomes among older patients with type 2 diabetes mellitus in Japan. <i>Current Medical Research and Opinion</i> , 2021, 37, 393-402.	1.9	1
8	Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study. <i>Diabetes Therapy</i> , 2021, 12, 183-196.	2.5	17
9	Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1). <i>Journal of the Endocrine Society</i> , 2021, 5, A10-A10.	0.2	0
10	Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials. <i>Cardiovascular Diabetology</i> , 2021, 20, 96.	6.8	16
11	Generation of disease-specific and CRISPR/Cas9-mediated gene-corrected iPS cells from a patient with adult progeria Werner syndrome. <i>Stem Cell Research</i> , 2021, 53, 102360.	0.7	8
12	Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke. <i>BMC Medicine</i> , 2021, 19, 131.	5.5	13
13	Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the <sc>EMPAâ€“REG OUTCOME</sc> trial with a focus on Asia. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1886-1891.	4.4	18
14	Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosis. <i>Scientific Reports</i> , 2021, 11, 13450.	3.3	14
15	Association between glycemic control and cardiovascular events in older Japanese adults with diabetes mellitus: An analysis of the Japanese medical administrative database. <i>Journal of Diabetes Investigation</i> , 2021, 12, 2036-2045.	2.4	4
16	Characteristics of benign adrenocortical adenomas with 18F-FDG PET accumulation. <i>European Journal of Endocrinology</i> , 2021, 185, 155-165.	3.7	7
17	ICAM1-Negative Intravascular Large B-Cell Lymphoma of the Pituitary Gland: A Case Report and Literature Review. <i>AACE Clinical Case Reports</i> , 2021, 7, 249-255.	1.1	1
18	Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1861.e1-1861.e5.	6.0	107

#	ARTICLE	IF	CITATIONS
19	Identification of clonal immunoglobulin λ light-chain gene rearrangements in AL amyloidosis using next-generation sequencing. <i>Experimental Hematology</i> , 2021, 101-102, 34-41.e4.	0.4	1
20	Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPAR α Modulator, Pemaifibrate. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 974-996.	2.0	10
21	Serum HDL-C values: An extremely useful marker for differentiating homozygous lipoprotein lipase deficiency from severe hypertriglyceridemia with other causes in Japan. <i>Clinica Chimica Acta</i> , 2021, 521, 85-89.	1.1	1
22	Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 mg in Adults With Overweight or Obesity (STEP 1). <i>Adipositas - Ursachen Folgeerkrankungen Therapie</i> , 2021, 15, .	0.2	0
23	Calcification in Werner syndrome associated with lymphatic vessels aging. <i>Aging</i> , 2021, 13, 25717-25728.	3.1	2
24	Low dose red yeast rice with monacolin K lowers LDL cholesterol and blood pressure in Japanese with mild dyslipidemia: A multicenter, randomized trial. <i>Asia Pacific Journal of Clinical Nutrition</i> , 2021, 30, 424-435.	0.4	3
25	A Case of Hashimoto's Thyroiditis with Multiple Drug Resistance and High Expression of Efflux Transporters. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 399-406.	3.6	3
26	Aldosterone Reduction Rate After Saline Infusion Test May Be a Novel Prediction in Patients With Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e319-e327.	3.6	17
27	Serum anti-LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases. <i>Cancer Science</i> , 2020, 111, 4453-4464.	3.9	16
28	Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema. <i>Case Reports in Ophthalmological Medicine</i> , 2020, 2020, 1-6.	0.5	10
29	Detailed analysis of lipolytic enzymes in a Japanese woman of familial lipoprotein lipase deficiency "Effects of pemaifibrate treatment. <i>Clinica Chimica Acta</i> , 2020, 510, 216-219.	1.1	5
30	Elevated levels of autoantibodies against DNAJC2 in sera of patients with atherosclerotic diseases. <i>Heliyon</i> , 2020, 6, e04661.	3.2	16
31	Dose-dependent reduction in body weight with LIK066 (licoglitflozin) treatment in Japanese patients with obesity. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1102-1110.	4.4	18
32	A case of generalized lipodystrophy-associated progeroid syndrome treated by leptin replacement with short and long-term monitoring of the metabolic and endocrine profiles. <i>Endocrine Journal</i> , 2020, 67, 211-218.	1.6	3
33	Association between serum anti-ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertension. <i>International Journal of Molecular Medicine</i> , 2020, 46, 1274-1288.	4.0	11
34	Guidelines on the Clinical Evaluation of Medicinal Products for Treatment of Dyslipidemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 1246-1254.	2.0	3
35	Efficacy and Safety of Pemaifibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARM α): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5537.	4.1	27
36	Syngaresinol Reverses Age-Related Skin Atrophy by Suppressing FoxO3a-Mediated Matrix Metalloproteinase-2 Activation in Copper/Zinc Superoxide Dismutase Deficient Mice. <i>Journal of Investigative Dermatology</i> , 2019, 139, 648-655.	0.7	25

#	ARTICLE	IF	CITATIONS
37	Multidrug use positively correlates with high-risk prescriptions in the Japanese elderly: a longitudinal study. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2019, 5, 20.	1.0	13
38	Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded endpoint, randomized controlled study (PRIME-V study). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1990-1995.	4.4	28
39	Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1737-1744.	4.4	35
40	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. <i>Diabetes Care</i> , 2019, 42, 1147-1154.	8.6	249
41	Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor- α Modulator (SPPARM α), in Dyslipidemic Patients with Renal Impairment. <i>International Journal of Molecular Sciences</i> , 2019, 20, 706.	4.1	53
42	KDM2B in polycomb repressive complex 1.1 functions as a tumor suppressor in the initiation of T-cell leukemogenesis. <i>Blood Advances</i> , 2019, 3, 2537-2549.	5.2	22
43	Characteristic Clinical Features of Werner Syndrome with a Novel Compound Heterozygous WRN Mutation c.1720+1G>A Plus c.3139-1G>C. <i>Internal Medicine</i> , 2019, 58, 1033-1036.	0.7	1
44	Discussion on Management of Metabolic and Endocrine Disorders for General Practitioners. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2019, 108, 729-746.	0.0	0
45	Metabolism and Endocrinology as Crossroads of Generalism and Specialism. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2019, 108, 663-665.	0.0	0
46	6. Update for the Management of Dyslipidemia. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2019, 108, 1896-1901.	0.0	0
47	A Novel Approach to the Treatment of Plasma Protein Deficiency: <i>Ex Vivo</i> -Manipulated Adipocytes for Sustained Secretion of Therapeutic Proteins. <i>Chemical and Pharmaceutical Bulletin</i> , 2018, 66, 217-224.	1.3	7
48	Effects of a novel selective peroxisome proliferator-activated receptor- α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. <i>Journal of Diabetes Investigation</i> , 2018, 9, 1323-1332.	2.4	32
49	Distinct roles of systemic and local actions of insulin on pancreatic β -cells. <i>Metabolism: Clinical and Experimental</i> , 2018, 82, 100-110.	3.4	7
50	Effects of Pemafibrate, a Novel Selective PPAR α Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. <i>Diabetes Care</i> , 2018, 41, 538-546.	8.6	122
51	Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 521-538.	2.0	97
52	Postpartum risk of diabetes and predictive factors for glucose intolerance in East Asian women with gestational diabetes. <i>Diabetes Research and Clinical Practice</i> , 2018, 140, 1-8.	2.8	18
53	Continuous glucose monitoring reveals hypoglycemia risk in elderly patients with type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2018, 9, 69-74.	2.4	25
54	Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. <i>Journal of Clinical Lipidology</i> , 2018, 12, 173-184.	1.5	127

#	ARTICLE	IF	CITATIONS
55	Accelerated oligosaccharide absorption and altered serum metabolites during oral glucose tolerance test in young Japanese with impaired glucose tolerance. <i>Journal of Diabetes Investigation</i> , 2018, 9, 512-521.	2.4	4
56	Association of serum levels of antibodies against MMP1, CBX1, and CBX5 with transient ischemic attack and cerebral infarction. <i>Oncotarget</i> , 2018, 9, 5600-5613.	1.8	38
57	Prednisolone-responsive Postpartum IgG4-related Hypophysitis. <i>Internal Medicine</i> , 2018, 57, 367-375.	0.7	14
58	Elevation of autoantibody level against PDCD11 in patients with transient ischemic attack. <i>Oncotarget</i> , 2018, 9, 8836-8848.	1.8	18
59	Transcription Factor 21 Is Required for Branching Morphogenesis and Regulates the Gdnf-Axis in Kidney Development. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2795-2808.	6.1	23
60	Development of the Dementia Assessment Sheet for Community-based Integrated Care System 8-items, a short version of the Dementia Assessment Sheet for Community-based Integrated Care System 21-items, for the assessment of cognitive and daily functions. <i>Geriatrics and Gerontology International</i> , 2018, 18, 1458-1462.	1.5	32
61	Altered cerebral blood flow in the anterior cingulate cortex is associated with neuropathic pain. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1082-1087.	1.9	30
62	Efficacy of Pemafibrate on Atherogenic Dyslipidemia: Results of a Pooled Analysis of Pemafibrate Phase II/III Clinical Trials Compared with Placebo. <i>Atherosclerosis Supplements</i> , 2018, 32, 25-26.	1.2	1
63	p53-inducible DPYSL4 associates with mitochondrial supercomplexes and regulates energy metabolism in adipocytes and cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 8370-8375.	7.1	41
64	Glucagonoma With Necrolytic Migratory Erythema: Metabolic Profile and Detection of Biallelic Inactivation of DAXX Gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2417-2423.	3.6	12
65	RECQ helicase disease and related progeroid syndromes: RECQ2018 meeting. <i>Mechanisms of Ageing and Development</i> , 2018, 173, 80-83.	4.6	13
66	Biallelic WRN Mutations in Newly Identified Japanese Werner Syndrome Patients. <i>Molecular Syndromology</i> , 2018, 9, 214-218.	0.8	5
67	Generation of Endothelial and Smooth Muscle Cells from Werner Syndrome-Specific Induced Pluripotent Stem Cells. <i>Juntendo Medical Journal</i> , 2018, 64, 207-215.	0.1	0
68	Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163, a marker for activated macrophage, in individuals with type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2017, 126, 138-143.	2.8	5
69	Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor β modulator (SPPARM β), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. <i>Atherosclerosis</i> , 2017, 261, 144-152.	0.8	101
70	Recent Trends in WRN Gene Mutation Patterns in Individuals with Werner Syndrome. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 1853-1856.	2.6	13
71	Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study). <i>BMJ Open</i> , 2017, 7, e015766.	1.9	6
72	Femoral osteoporosis is more common than lumbar osteoporosis in patients with Werner syndrome. <i>Geriatrics and Gerontology International</i> , 2017, 17, 854-856.	1.5	6

#	ARTICLE	IF	CITATIONS
73	A Toxic Conformer of A β 242 with a Turn at 22-23 is a Novel Therapeutic Target for Alzheimer's Disease. <i>Scientific Reports</i> , 2017, 7, 11811.	3.3	23
74	The obesity-related pathology and Th17 cells. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 1231-1245.	5.4	65
75	WRN Mutation Update: Mutation Spectrum, Patient Registries, and Translational Prospects. <i>Human Mutation</i> , 2017, 38, 7-15.	2.5	79
76	Altered serum level of matrix metalloproteinase-9 and its association with decision-making in eating disorders. <i>Psychiatry and Clinical Neurosciences</i> , 2017, 71, 124-134.	1.8	10
77	Platinum and Palladium Nanoparticles Regulate the Redox Balance and Protect Against Age-Related Skin Changes in Mice. , 2017, , 457-467.		0
78	Improved Glycemic Control and Vascular Function and Reduction of Abdominal Fat Accumulation with Liraglutide in a Case of Werner Syndrome with Diabetes Mellitus. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 687-688.	2.6	6
79	Fatty acid metabolic reprogramming via mTOR-mediated inductions of PPAR δ directs early activation of T cells. <i>Nature Communications</i> , 2016, 7, 13683.	12.8	194
80	Cushing Syndrome Due to ACTH-Secreting Pheochromocytoma, Aggravated by Glucocorticoid-Driven Positive-Feedback Loop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 841-846.	3.6	32
81	Effects of K-877, a novel selective PPAR δ modulator (SPPARM δ), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. <i>Atherosclerosis</i> , 2016, 249, 36-43.	0.8	146
82	Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia. <i>Leukemia Research</i> , 2016, 50, 85-94.	0.8	15
83	Elevated Adiponectin Antibody Levels in Sera of Patients with Atherosclerosis-Related Coronary Artery Disease, Cerebral Infarction and Diabetes Mellitus. <i>Journal of Circulating Biomarkers</i> , 2016, 5, 8.	1.3	12
84	Comparison of Drug Use Between Clinical Practice and Regulatory Approval: Results in Older Japanese Patients With Rheumatoid Arthritis, Diabetes, High Blood Pressure, or Depression. <i>Therapeutic Innovation and Regulatory Science</i> , 2016, 50, 743-750.	1.6	1
85	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin): A multicenter, randomized, open-label, non-inferiority trial. <i>Journal of Diabetes Investigation</i> , 2015, 6, 182-191.	2.4	18
86	Unsuppressed lipolysis in adipocytes is linked with enhanced gluconeogenesis and altered bile acid physiology in <i>InsrP1195L/+</i> mice fed high-fat-diet. <i>Scientific Reports</i> , 2015, 5, 17565.	3.3	14
87	Astaxanthin Improves Nonalcoholic Fatty Liver Disease in Werner Syndrome with Diabetes Mellitus. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 1271-1273.	2.6	16
88	Pituitary Adenylate Cyclase-Activating Polypeptide Protects Glomerular Podocytes from Inflammatory Injuries. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-10.	2.3	18
89	Cell biology of diabetic nephropathy: Roles of endothelial cells, tubulointerstitial cells and podocytes. <i>Journal of Diabetes Investigation</i> , 2015, 6, 3-15.	2.4	161
90	Pioglitazone Improves Fat Tissue Distribution and Hyperglycemia in a Case of Cockayne Syndrome With Diabetes. <i>Diabetes Care</i> , 2015, 38, e76-e76.	8.6	4

#	ARTICLE	IF	CITATIONS
91	Werner Syndrome-specific induced pluripotent stem cells: recovery of telomere function by reprogramming. <i>Frontiers in Genetics</i> , 2015, 6, 10.	2.3	32
92	<i>Helicobacter cinaedi</i> infection in patients with diabetes: a case report. <i>SpringerPlus</i> , 2015, 4, 72.	1.2	6
93	Comparison in decision-making between bulimia nervosa, anorexia nervosa, and healthy women: influence of mood status and pathological eating concerns. <i>Journal of Eating Disorders</i> , 2015, 3, 14.	2.7	14
94	Obesity Drives Th17 Cell Differentiation by Inducing the Lipid Metabolic Kinase, ACC1. <i>Cell Reports</i> , 2015, 12, 1042-1055.	6.4	182
95	Platinum and Palladium Nanoparticles Regulate the Redox Balance and Protect Against Age-Related Skin Changes in Mice. , 2015, , 1-11.		0
96	Superoxide Dismutase 1 Loss Disturbs Intracellular Redox Signaling, Resulting in Global Age-Related Pathological Changes. <i>BioMed Research International</i> , 2014, 2014, 1-10.	1.9	38
97	Tetraspanin CD9 modulates ADAM17-mediated shedding of LR11 in leukocytes. <i>Experimental and Molecular Medicine</i> , 2014, 46, e89-e89.	7.7	25
98	Efficacy of HMG-CoA reductase inhibitors in the prevention of cerebrovascular attack in 1016 patients older than 75 years among 4014 type 2 diabetic individuals. <i>International Journal of Cardiology</i> , 2014, 177, 860-866.	1.7	1
99	A method for estimating visceral fat from the elasticity of lumbar subcutaneous fat. <i>Artificial Life and Robotics</i> , 2014, 19, 1-8.	1.2	1
100	Sod1 Loss Induces Intrinsic Superoxide Accumulation Leading to p53-Mediated Growth Arrest and Apoptosis. <i>International Journal of Molecular Sciences</i> , 2013, 14, 10998-11010.	4.1	30
101	Soluble LR11, a Novel Acute Leukemia Marker, Drastically Induces WT1 mRNA Expression Together with Synergic Activation of Gatas, and the Migration Activity. <i>Blood</i> , 2012, 120, 4795-4795.	1.4	8
102	Ezh2 Plays a Critical Role in the Progression of MLL-AF9-Induced Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 57-57.	1.4	0
103	The Role of Smad3-Dependent TGF- β Signal in Vascular Response to Injury. <i>Trends in Cardiovascular Medicine</i> , 2006, 16, 240-245.	4.9	17
104	NK-104, a 3 α -hydroxy- β -methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells. <i>British Journal of Pharmacology</i> , 2001, 133, 83-88.	5.4	25
105	Enhanced Expression of Osteopontin in Human Diabetic Artery and Analysis of Its Functional Role in Accelerated Atherogenesis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 624-628.	2.4	108
106	Enhanced Expression of Osteopontin by High Glucose: Involvement of Osteopontin in Diabetic Macroangiopathy. <i>Annals of the New York Academy of Sciences</i> , 2000, 902, 357-363.	3.8	30
107	Fibroblast growth factor receptor-1 mediates chemotaxis independently of direct SH2-domain protein binding. <i>Oncogene</i> , 1998, 17, 283-291.	5.9	52
108	Diabetic Control and Progression of Retinopathy in Elderly Patients: Five-Year Follow-up Study. <i>Journal of the American Geriatrics Society</i> , 1994, 42, 142-145.	2.6	45

#	ARTICLE	IF	CITATIONS
109	Lipoprotein(a) Is a Risk Factor for Diabetic Retinopathy in the Elderly. Journal of the American Geriatrics Society, 1994, 42, 965-967.	2.6	10
110	The phospholipase-A2 reaction leads to increased monocyte adhesion of endothelial cells via the expression of adhesion molecules. FEBS Journal, 1993, 217, 723-729.	0.2	53
111	Predictive model and risk engine web application for surgical site infection risk in perioperative patients with type 2 diabetes. Diabetology International, 0, , .	1.4	0